The National Institutes of Health today announced a new public-private partnership, the goal of which is to meet the urgent need for early therapeutic interventions for people at risk of developing schizophrenia.

NIH’s Accelerating Medicines Partnership program will administer AMP Schizophrenia to leverage resources and expertise from NIH, the Food and Drug Administration and multiple non-profit and private organizations. Their goal is to identify promising biological markers that can help identify those at risk of developing schizophrenia as early as possible, track the progression of symptoms and other outcomes, and define targets for treatment development.

The initiative also will seek to develop measures that further define early stages of risk while predicting the likelihood of progression to psychosis and other outcomes.

 

Related News Articles

Headline
U.S. life expectancy fell by an average of 1.5 years in 2020 to 77.3 years, primarily due to COVID-19, the Centers for Disease Control and Prevention reported…
News
Reps. Cheri Bustos, D-Ill., Tom Cole, R-Okla., G.K. Butterfield, D-N.C., and Markwayne Mullin, R-Okla., today launched the bipartisan Congressional Social…
Headline
The Centers for Disease Control and Prevention Saturday recommended clinicians consider monkeypox in patients with symptoms who traveled from Lagos Murtala…
Headline
The Centers for Disease Control and Prevention and Texas Department of State Health Services yesterday confirmed a case of human monkeypox in a U.S. resident…
Headline
The Centers for Disease Control and Prevention today released recommendations and guidance for treating plague, which has a high fatality rate if untreated but…
Headline
The House Energy and Commerce Subcommittee on Health today voted to advance to the full committee a number of AHA-supported bills focused on maternal health…